Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure

International Heart Journal

Volumn 49, Issue 1, 2008, Pages 49-58

  Aoyagi, Teruhiko ^a   Nakamura, Fumitaka ^b   Tomaru, Takanobu ^c   Toyo Oka, Teruhiko ^d  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Brain natriuretic peptide; Ejection fraction; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PITAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ENZYME INHIBITOR; LIPID; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; ISCHEMIC HEART DISEASE; M MODE ECHOCARDIOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; LIPIDS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; QUINOLINES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 43249115660     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.49     Document Type: Article

References (37)

1. Liao JK Statin therapy for cardiao phypertrophy and heart failure. J Investig Med 2004; 52: 248-53.
2. Egashira K, Hirooka Y, Kai H, et al. Reduction in scrum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholestorolemia. Circulation 1994; 89: 2519-24.
3. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77: 37-40.
4. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005; 179: 201-6.
5. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.
6. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
7. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
9. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-63.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7-22.
11. Node K, Fujita, M, Kitakaze M, Hori M, Liao JK. Short-term stitin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
12. Wojnicz R, Wilczek K, Nowalany-Kozielska I, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97: 899-904.
13. Khush KK, Waters DD, Bittaer V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) Study. Circulation 2007; 115: 576-83.
14. Sakamoto T, Kojima. S, Ogawa, H, et al; Multicenter Study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors in patients with acute myocardial infarction investigators. Effects of early statin treatment on symptomatic heart fiulure and ischemic events after acute myocardial infarction in Japanese Am J Cardiol 2006; 97: 1165-71.
15. Fujino, H, Yamada, I, Shimada, S, Yoneda, M. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay - inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. J Chromatogr B Biomed Sci Appl 2001; 757: 143-50.
16. Tsutamoto T, Wada, A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
17. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-8.
18. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005; 165: 62-7.
19. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-63.
20. Eroglu S, Yildirir A, Bozbas H, et al. Brain natriuretic peptide levels ahd cardiac functional capacity in patients with dyspnea and isolated diastolic dysfunction. Int Heart J 2007; 48: 97-106.
21. Kuklinska AM, Sobkowicz B, Kaminski KA, et al. The benefits of repeated measurements of B-type natriuretic peptide in patients with first ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Int Heart J 2006; 47: 843-54.
22. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142-6.
23. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-8.
24. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Rcs 2005; 97: 1232-5.
25. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-5.
26. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000; 106: 15-24.
27. Hernádez-Perera O, Pérez-Sala D, Soria E, Lamas S. Involvement of Rho GFPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial oells. Circ Res 2000; 87: 616-22.
28. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-9.
29. Laufs U, Wassman S, Hilgers S, Ribaudo N, Bohm M, Nickenig G Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88: 1306-7.
30. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-103.
31. Wassmann S, Faul A, Bennen B, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-54.
32. Takemoto M, Node, K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 2001; 108: 1429-37.
33. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment Circulation 2003; 108: 1567-74.
34. Deswal A, Petersen NJ, Feldman AM, Young JB, White BC, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
35. Rauchhause M, Doehner W, Francis DP, et al. Plasm cytokine parameters and mortality in patients with chronic, heart failure. Circulation 2000; 102: 3060-7.
36. Abe Y, Izumi T, Urabe A, et al. Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress. Cardiovasc Drugs Ther 2006; 20: 273-80.
37. Saka M, Obata K, Ichihara, S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47: 770-9.